Target intelligence / Profile preview

Organic cation transporter 1-3 (OCT1-3) (OCT1-3)

Target
OCT1-3
Molecular classification
Transporter, Solute carrier family
01

Overview

The Organic Cation Transporters 1, 2, and 3 (OCT1-3) are a group of polyspecific transporters belonging to the Solute Carrier Family 22 (SLC22A1, SLC22A2, and SLC22A3) that play a fundamental role in the movement of organic cations across cell membranes [1, 4]. These transporters operate via facilitated diffusion, driven by the electrochemical gradient of the substrate, and are independent of sodium or proton gradients [2, 4]. OCT1 is primarily expressed in the liver and is crucial for the hepatic uptake of the first-line antidiabetic drug metformin and several tyrosine kinase inhibitors used in cancer therapy [5, 15]. OCT2 is predominantly localized in the kidney, where it facilitates the renal secretion of cationic drugs and is a major mediator of cisplatin-induced nephrotoxicity [8, 18]. OCT3, also known as the extraneuronal monoamine transporter (EMT), has a broad tissue distribution and is involved in the clearance of monoamine neurotransmitters such as dopamine and serotonin in the brain and heart [11, 18]. Collectively, these transporters are critical in pharmacokinetics, influencing drug absorption, distribution, and elimination [6, 8]. They are also significant sites for clinically relevant drug-drug interactions, where one drug can inhibit the transport of another, leading to altered efficacy or toxicity [5, 14]. Furthermore, common genetic polymorphisms in the SLC22A1-3 genes contribute to significant inter-individual variability in drug response and susceptibility to adverse effects [7, 19].

Other names
SLC22A1SLC22A2SLC22A3Solute carrier family 22 members 1-3OCT1OCT2OCT3EMTExtraneuronal monoamine transporter
02

Mechanism of action

Facilitated diffusion of organic cations across the plasma membrane driven by the electrochemical gradient of the substrate.

03

Biological functions

Transport of organic cationsDrug dispositionNeurotransmitter clearanceMetabolic waste elimination
04

Disease associations

DiabetesCancerNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Drug-drug interactionsNephrotoxicityHepatotoxicityGenetic polymorphism-induced variability in drug response
06

Interacting drugs

Metformin

10 more in the full profile.

07

Biomarkers

SLC22A1 genetic variantsSLC22A2 genetic variantsSerum creatinine

Beyond the preview

Go deeper on Organic cation transporter 1-3 (OCT1-3) (OCT1-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Organic cation transporter 1-3 (OCT1-3) (OCT1-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call